$RLFTF Good DD by Gemstone (post)
I highly recommend that everyone watch Dr. Javitt’s interview with Dr. Yo for themselves. I carefully listened to the interview, and heard several positive statements. In my opinion, Dr. Javitt’s disposition was the same as in his previous interview with Dr. Yo.
1) Dr. Javitt stated that in order to obtain an FDA EUA, the requirement is that the drug is safe and “MAY” be effective. He further explained that they ALREADY have evidence to meet these requirements for the FDA EUA, and referenced the clinical data available from the 21 patients treated with RLF-100 under the expanded access program. Thus, the data expected at the end of October from the ongoing clinical trial is NOT needed for FDA EUA, but will be used to meet the full FDA drug approval standard of “safe and effective”.
2) Israel has granted compassionate care protocol across the country for RLF-100.
3) The company has a cooperative agreement with NIH, where NIH is testing RLF-100 against the flu and other viruses (that kill people by attacking the lungs). If effective, there will be a broader use for the drug.
4) Doctors in Germany have used VIP in an inhaled form on a limited number of patients, and those patients are all back home.
5) Dr. Javitt reiterated the following information:
One of the most interesting things they’ve seen is that patients who have survived critical COVID-19 after being on ventilators, had twice the amount of VIP in their bloodstream than similar patients who died.
Dr. Javitt stated that VIP is how the lung recovers from all kinds of injuries. On an evolutionary basis, he views VIP as a perfect molecule.
SARS-CoV-2 binds to the ACE2 receptor on alveolar type 2 cells. The alveolar type 2 cells are critical to the function of the lungs. When the virus goes inside the alveolar type 2 cells, it shuts down the production of surfactant in the lungs. The surfactant keeps the lung coated and allows oxygen to pass across the lung. When you no longer produce surfactant, you cannot oxygenate your blood and that is the beginning of COVID-19 complications. If they can preserve the alveolar type 2 cells early in the disease, there is a chance they can make a significant impact on COVID-19.
Dr. Javitt interview
https://youtu.be/lrtsexJOxU8
I highly recommend that everyone watch Dr. Javitt’s interview with Dr. Yo for themselves. I carefully listened to the interview, and heard several positive statements. In my opinion, Dr. Javitt’s disposition was the same as in his previous interview with Dr. Yo.
1) Dr. Javitt stated that in order to obtain an FDA EUA, the requirement is that the drug is safe and “MAY” be effective. He further explained that they ALREADY have evidence to meet these requirements for the FDA EUA, and referenced the clinical data available from the 21 patients treated with RLF-100 under the expanded access program. Thus, the data expected at the end of October from the ongoing clinical trial is NOT needed for FDA EUA, but will be used to meet the full FDA drug approval standard of “safe and effective”.
2) Israel has granted compassionate care protocol across the country for RLF-100.
3) The company has a cooperative agreement with NIH, where NIH is testing RLF-100 against the flu and other viruses (that kill people by attacking the lungs). If effective, there will be a broader use for the drug.
4) Doctors in Germany have used VIP in an inhaled form on a limited number of patients, and those patients are all back home.
5) Dr. Javitt reiterated the following information:
One of the most interesting things they’ve seen is that patients who have survived critical COVID-19 after being on ventilators, had twice the amount of VIP in their bloodstream than similar patients who died.
Dr. Javitt stated that VIP is how the lung recovers from all kinds of injuries. On an evolutionary basis, he views VIP as a perfect molecule.
SARS-CoV-2 binds to the ACE2 receptor on alveolar type 2 cells. The alveolar type 2 cells are critical to the function of the lungs. When the virus goes inside the alveolar type 2 cells, it shuts down the production of surfactant in the lungs. The surfactant keeps the lung coated and allows oxygen to pass across the lung. When you no longer produce surfactant, you cannot oxygenate your blood and that is the beginning of COVID-19 complications. If they can preserve the alveolar type 2 cells early in the disease, there is a chance they can make a significant impact on COVID-19.
Dr. Javitt interview
https://youtu.be/lrtsexJOxU8
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
